Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3► The biomarker signatures suggested strong predictive accuracy, with AUROC values above 0.80 that may indicate...

DAIX, 24/04/2025 (informazione.news - comunicati stampa - salute e benessere)

► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis

► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3

► The biomarker signatures suggested strong predictive accuracy, with AUROC values above 0.80 that may indicate high reliability in distinguishing responders from non-responders

► The analysis confirmed that histological response to lanifibranor could be assessed with non-invasive signatures based on blood markers

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced publication in the peer-reviewed medical journal Clinical Gastroenterology and Hepatology, of its analysis on new non-invasive biomarker signatures predictive of histology response following treatment with lanifibranor in patients with MASH and fibrosis.

: “
                                                                        
The analysis assessed 71 biomarkers of interest (65 laboratory parameters and 6 diagnostic scores) measured in the Phase 2b NATIVE at baseline and after 24 weeks of treatment with lanifibranor 800mg and 1200mg/daily, in order to select biomarkers predictive of histological responses: MASH resolution with fibrosis improvement (E1), MASH resolution without fibrosis worsening (E2), and fibrosis improvement alone without worsening of MASH (E3).

The biomarkers included E1-score (baseline adiponectin and ferritin; delta of matrix metalloproteinase 9 and transferrin), E2-score (baseline cytokeratin 18 Fragment M65; delta of hyaluronic acid, fructosamine and ALT) and E3-score (baseline cytokeratin 18 Fragment M65 and gamma-GT; delta of AST, insulin, and urea) representing metabolic, apoptotic and fibrosis aspects of the disease. These signatures were observed to provide good accuracy for the non-invasive identification of histological response under lanifibranor with AUROC at 0.81±0.08, 0.80±0.08 and 0.81±0.08 respectively.

Developing such biomarker signatures could provide a non-invasive method to help physicians identify patients most likely to benefit from lanifibranor treatment. This approach supports precision medicine strategies in liver disease management.

Lanifibranor, Inventiva's lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor's moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and pre-clinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. 

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3
clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.  

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).  www.inventivapharma.com

Attachment